• Source: Tabalumab

Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies. Tabalumab was developed by Eli Lilly and Company.
A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013. In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.




References



Now dropped by Lilly due to lack of efficacy.

Kata Kunci Pencarian:

• Tabalumab
• Tumor necrosis factor
• Pegipanermin
• List of therapeutic monoclonal antibodies
• Tumor necrosis factor superfamily
• List of drugs: T–Td
• TNF receptor superfamily
• C6518H10008N1724O2032S38
• Lymphotoxin alpha
• Theralizumab